Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rhea-AI Summary
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options on May 21, 2026, for thirteen new non-executive employees, covering an aggregate of 93,340 shares of common stock.
The options, granted under the 2021 Inducement Plan, have a $3.70 exercise price and vest over three years with time-based milestones.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
IOVA gained about 4.52% while several close biotech peers declined: SANA -3.76%, IMNM -5.74%, NKTR -2.04%, URGN -3.18%. Only EYPT was modestly higher at +0.47%, suggesting stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 21 | Conference appearance | Neutral | +4.5% | Management scheduled for Jefferies healthcare conference fireside chat and webcast. |
| May 07 | Earnings and guidance | Positive | -13.2% | Q1 2026 revenue growth, guidance, and clinical updates highlighted as positive. |
| Apr 27 | Earnings date set | Neutral | -0.3% | Company scheduled Q1 2026 results call and webcast for investors. |
| Apr 17 | Inducement grants | Neutral | -2.1% | Inducement options for 135,470 shares granted to new non-executive employees. |
| Mar 20 | Inducement grants | Neutral | -1.6% | Inducement options for 3,400 shares granted to a new employee. |
Recent history shows at least one positive fundamental update (earnings) followed by a negative price reaction, while smaller operational items like inducement grants have seen modest declines or mixed moves.
Over the last few months, Iovance has reported key milestones, including Q1 2026 earnings with strong revenue growth and guidance, an upcoming June 4, 2026 conference appearance, and multiple inducement grant announcements under its 2021 Inducement Plan. The prior earnings release on May 7, 2026 led to a -13.2% move despite positive metrics, while earlier inducement grants on April 16 and March 19, 2026 coincided with smaller declines. Today’s grants continue this pattern of routine equity-based hiring updates.
Market Pulse Summary
This announcement outlines routine inducement stock options for new hires, covering 93,340 shares at an exercise price of $3.70, vesting over three years with an initial one‑third tranche followed by eight quarterly installments. It continues a series of similar grants under the 2021 Inducement Plan. Investors may watch how cumulative equity awards interact with existing authorization proposals and overall hiring and growth plans.
Key Terms
inducement stock options financial
nasdaq listing rule 5635(c)(4) regulatory
exercise price financial
AI-generated analysis. Not financial advice.
SAN CARLOS, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on May 21, 2026 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 93,340 shares of Iovance’s common stock to thirteen new, non-executive employees.
The awards were granted under Iovance’s Amended and Restated 2021 Inducement Plan, which provides for the granting of equity awards to new employees of Iovance by the Company’s compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the “Company,” “we,” “us,” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as “predicts,” “believes,” “potential,” “achievable,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “can,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
CONTACTS
Investors
IR@iovance.com
650-260-7120 ext. 150
Media
PR@iovance.com
650-260-7120 ext. 150
